BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 30362375)

  • 1. ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.
    Farago AF; Drapkin BJ; Lopez-Vilarino de Ramos JA; Galmarini CM; Núñez R; Kahatt C; Paz-Ares L
    Future Oncol; 2019 Jan; 15(3):231-239. PubMed ID: 30362375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
    Gaillard S; Oaknin A; Ray-Coquard I; Vergote I; Scambia G; Colombo N; Fernandez C; Alfaro V; Kahatt C; Nieto A; Zeaiter A; Aracil M; Vidal L; Pardo-Burdalo B; Papai Z; Kristeleit R; O'Malley DM; Benjamin I; Pautier P; Lorusso D
    Gynecol Oncol; 2021 Nov; 163(2):237-245. PubMed ID: 34521554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
    Trigo J; Subbiah V; Besse B; Moreno V; López R; Sala MA; Peters S; Ponce S; Fernández C; Alfaro V; Gómez J; Kahatt C; Zeaiter A; Zaman K; Boni V; Arrondeau J; Martínez M; Delord JP; Awada A; Kristeleit R; Olmedo ME; Wannesson L; Valdivia J; Rubio MJ; Anton A; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D'Arcangelo M; Santoro A; Villalobos VM; Sands J; Paz-Ares L
    Lancet Oncol; 2020 May; 21(5):645-654. PubMed ID: 32224306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
    Aix SP; Ciuleanu TE; Navarro A; Cousin S; Bonanno L; Smit EF; Chiappori A; Olmedo ME; Horvath I; Grohé C; Farago AF; López-Vilariño JA; Cullell-Young M; Nieto A; Vasco N; Gómez J; Kahatt C; Zeaiter A; Carcereny E; Roubec J; Syrigos K; Lo G; Barneto I; Pope A; Sánchez A; Kattan J; Zarogoulidis K; Waller CF; Bischoff H; Juan-Vidal O; Reinmuth N; Dómine M; Paz-Ares L
    Lancet Respir Med; 2023 Jan; 11(1):74-86. PubMed ID: 36252599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
    Olmedo ME; Forster M; Moreno V; López-Criado MP; Braña I; Flynn M; Doger B; de Miguel M; López-Vilariño JA; Núñez R; Kahatt C; Cullell-Young M; Zeaiter A; Calvo E
    Invest New Drugs; 2021 Oct; 39(5):1275-1283. PubMed ID: 33704620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
    Peters S; Trigo J; Besse B; Moreno V; Navarro A; Eugenia Olmedo M; Paz-Ares L; Grohé C; Antonio Lopez-Vilariño J; Fernández C; Kahatt C; Alfaro V; Nieto A; Zeaiter A; Subbiah V
    Lung Cancer; 2024 Feb; 188():107448. PubMed ID: 38198859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
    Kristeleit R; Moreno V; Boni V; Guerra EM; Kahatt C; Romero I; Calvo E; Basté N; López-Vilariño JA; Siguero M; Alfaro V; Zeaiter A; Forster M
    Int J Gynecol Cancer; 2021 Nov; 31(11):1428-1436. PubMed ID: 34610971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
    Calvo E; Moreno V; Flynn M; Holgado E; Olmedo ME; Lopez Criado MP; Kahatt C; Lopez-Vilariño JA; Siguero M; Fernandez-Teruel C; Cullell-Young M; Soto Matos-Pita A; Forster M
    Ann Oncol; 2017 Oct; 28(10):2559-2566. PubMed ID: 28961837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501.
    Gervais R; Le Caer H; Monnet I; Falchero L; Baize N; Olivero G; Thomas P; Berard H; Auliac JB; Chouaid C;
    Clin Lung Cancer; 2015 Mar; 16(2):100-5. PubMed ID: 25467927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lurbinectedin in the treatment of relapsed small cell lung cancer.
    Baena J; Modrego A; Zeaiter A; Kahatt C; Alfaro V; Jimenez-Aguilar E; Mazarico JM; Paz-Ares L
    Future Oncol; 2021 Jun; 17(18):2279-2289. PubMed ID: 33736462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
    Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
    PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
    Hanvesakul R; Rengarajan B; Naveh N; Boccuti A; Park JE; Adeyemi A; Caisip C; Jansen JP; Wilson FR
    J Comp Eff Res; 2023 May; 12(5):e220098. PubMed ID: 37079341
    [No Abstract]   [Full Text] [Related]  

  • 13. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
    Cote GM; Choy E; Chen T; Marino-Enriquez A; Morgan J; Merriam P; Thornton K; Wagner AJ; Nathenson MJ; Demetri G; George S
    Eur J Cancer; 2020 Feb; 126():21-32. PubMed ID: 31896519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
    Cruz C; Llop-Guevara A; Garber JE; Arun BK; Pérez Fidalgo JA; Lluch A; Telli ML; Fernández C; Kahatt C; Galmarini CM; Soto-Matos A; Alfaro V; Pérez de la Haza A; Domchek SM; Antolin S; Vahdat L; Tung NM; Lopez R; Arribas J; Vivancos A; Baselga J; Serra V; Balmaña J; Isakoff SJ
    J Clin Oncol; 2018 Nov; 36(31):3134-3143. PubMed ID: 30240327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lurbinectedin for the treatment of small cell lung cancer.
    Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
    Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer.
    Patel S; Petty WJ; Sands JM
    Ther Adv Med Oncol; 2021; 13():17588359211020529. PubMed ID: 34104228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.
    von Pawel J; Schiller JH; Shepherd FA; Fields SZ; Kleisbauer JP; Chrysson NG; Stewart DJ; Clark PI; Palmer MC; Depierre A; Carmichael J; Krebs JB; Ross G; Lane SR; Gralla R
    J Clin Oncol; 1999 Feb; 17(2):658-67. PubMed ID: 10080612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice.
    Toublanc AC; Guecamburu M; Veillon R; Rosellini P; Girodet PO; Zysman M
    Thorac Cancer; 2022 Aug; 13(15):2248-2252. PubMed ID: 35715960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan and cisplatin vs. cyclophosphamide, doxorubicin, and vincristine as second-line treatment after platinum and etoposide in small-cell lung cancer.
    Bilgi O; Karagoz B; Alacacioglu A; Ozgun A; Tuncel T; Gokhan-Kandemir E
    J BUON; 2010; 15(2):395. PubMed ID: 20658743
    [No Abstract]   [Full Text] [Related]  

  • 20. Lurbinectedin in small cell lung cancer.
    Manzo A; Sforza V; Carillio G; Palumbo G; Montanino A; Sandomenico C; Costanzo R; Esposito G; Laudato F; Mercadante E; La Manna C; Muto P; Totaro G; De Cecio R; Picone C; Piccirillo MC; Pascarella G; Normanno N; Morabito A
    Front Oncol; 2022; 12():932105. PubMed ID: 36110944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.